Study: U.S. Faces Higher Drug Shortages
November 1, 2024
-
2 min
5 Key Takeaways
-
1
Drug shortage risks were compared between the U.S. and Canada from 2017 to 202
-
2
The U.S. experienced approximately a 40% higher drug shortage risk compared to Canada.
-
3
Canada's approach included mandatory reporting, targeted stockpiling, and public payer collaboration.
-
4
The study highlighted that sole-source drugs faced a higher risk of shortage in both countries.
-
5
Canada's approach was associated with a lower shortage risk.
A recent study compared drug shortage risks following supply chain disruptions between the U.S. and Canada from 2017 to 2021. The findings indicated that the U.S. experienced approximately a 40% higher drug shortage risk compared to Canada, with trends persisting both pre-pandemic and during COVID-19. The study also highlighted that sole-source drugs faced a higher risk of shortage in both countries. Canada's approach, characterized by mandatory reporting, targeted stockpiling, and public payer collaboration, was associated with a lower shortage risk. These differences in drug shortage risks may inform future policy discussions on mitigating supply chain disruptions.
Listen Tab content